RIBOLIFE-B Surges Over 4% in Morning Trade as Mid-Year Net Profit Turns Positive at RMB 23 Million

Deep News

Sep 02

Shares of RIBOLIFE-B (06938) climbed as much as 5% during the trading session, with the stock last up 3.73% at HK$62.60, reflecting a turnover of approximately HK$11.08 million. The company recently disclosed its interim results for fiscal year 2026, reporting revenue of RMB 420 million, a 304% year-on-year increase. Net profit for the period stood at RMB 23 million, marking a turnaround from a loss in the prior year, while cash and cash equivalents at period-end reached RMB 2.24 billion.

The improvement in financial performance is primarily attributed to the recognition of licensing revenue from global collaboration projects and the continued advancement of cooperative milestones. Meanwhile, the company has maintained its research and development investments in core clinical pipelines and its innovative delivery platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/news/1156963993"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156963993\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156963993?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156963993","market":"fut","top_or_hot":-1,"title":"RIBOLIFE-B Surges Over 4% in Morning Trade as Mid-Year Net Profit Turns Positive at RMB 23 Million","media":"Deep News","content":"<p>Shares of <b>RIBOLIFE-B</b> (06938) climbed as much as 5% during the trading session, with the stock last up 3.73% at HK$62.60, reflecting a turnover of approximately HK$11.08 million. The company recently disclosed its interim results for fiscal year 2026, reporting revenue of RMB 420 million, a 304% year-on-year increase. Net profit for the period stood at RMB 23 million, marking a turnaround from a loss in the prior year, while cash and cash equivalents at period-end reached RMB 2.24 billion.<br><br>The improvement in financial performance is primarily attributed to the recognition of licensing revenue from global collaboration projects and the continued advancement of cooperative milestones. Meanwhile, the company has maintained its research and development investments in core clinical pipelines and its innovative delivery platform.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B Surges Over 4% in Morning Trade as Mid-Year Net Profit Turns Positive at RMB 23 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B Surges Over 4% in Morning Trade as Mid-Year Net Profit Turns Positive at RMB 23 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-02 11:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>RIBOLIFE-B</b> (06938) climbed as much as 5% during the trading session, with the stock last up 3.73% at HK$62.60, reflecting a turnover of approximately HK$11.08 million. The company recently disclosed its interim results for fiscal year 2026, reporting revenue of RMB 420 million, a 304% year-on-year increase. Net profit for the period stood at RMB 23 million, marking a turnaround from a loss in the prior year, while cash and cash equivalents at period-end reached RMB 2.24 billion.<br><br>The improvement in financial performance is primarily attributed to the recognition of licensing revenue from global collaboration projects and the continued advancement of cooperative milestones. Meanwhile, the company has maintained its research and development investments in core clinical pipelines and its innovative delivery platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1156963993","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156963993","pubTimestamp":1788318619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of RIBOLIFE-B (06938) climbed as much as 5% during the trading session, with the stock last up 3.73% at HK$62.60, reflecting a turnover of approximately HK$11.08 million. The company recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06938":"瑞博生物-B"},"translate_title":"RIBOLIFE-B早盘飙升逾4%，年中净利润转正至2300万元人民币","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"Shares of RIBOLIFE-B (06938) climbed as much as 5% during the trading session, with the stock last up 3.73% at HK$62.60, reflecting a turnover of approximately HK$11.08 million. The company recently disclosed its interim results for fiscal year 2026, reporting revenue of RMB 420 million, a 304% year-on-year increase. Net profit for the period stood at RMB 23 million, marking a turnaround from a loss in the prior year, while cash and cash equivalents at period-end reached RMB 2.24 billion.The improvement in financial performance is primarily attributed to the recognition of licensing revenue from global collaboration projects and the continued advancement of cooperative milestones. Meanwhile, the company has maintained its research and development investments in core clinical pipelines and its innovative delivery platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}